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Available online 21 May 2016There is a broad range of possible diagnoses for an elevated beta human chorionic gonadotropin (β-hCG) in the
absence of intrauterine or ectopic pregnancy. When women of child bearing potential undergo evaluation for
clinical trial, it is often unclear what course of evaluation to take when a pregnancy test is positive. We describe
the clinical course of a patient with widely metastatic mucinous ovarian carcinoma with metastasis to the peri-
toneum, lymph nodes and liver. The patient was found to have a mildly elevated β-hCG during initial evaluation
for clinical trial. Extensive work up for ectopic pregnancy, trophoblastic disease, and phantom β-hCG were neg-
ative. The patient'sβ-hCG levels continued to rise until initiation of therapy. Shewas treated on a phase I protocol
with restaging scans revealing a partial response. The β-hCG was retested and declined in conjunction with her
response, consistent with paraneoplastic β-hCG. Here, we propose a decisionmaking algorithm to evaluate a pa-
tient with an elevated β-hCG undergoing assessment for clinical trial.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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When evaluating patients for clinical trial, intrauterine pregnancy is
commonly considered an exclusion criteria, however guidelines do not
exist to determinewhat to do should a pregnancy test result as positive.
We describe a clinical case of a patient with metastatic mucinous
ovarian carcinoma. The patient underwent standard-of-care therapy
upfront with progression of disease and was referred to investigational
therapeutics for phase I treatment. Shewas found to have an elevatedβ-
hCG consistent with pregnancy. Pelvic ultrasound and β-hCG
heterophilic antibody testing were negative ruling out intrauterine
and ectopic pregnancy or phantom hCG. Her elevated β-hCG appeared
consistent with paraneoplastic syndrome reﬂected in a decline in β-
hCG that correlated with a response to treatment.
2. Case report
A 34-year-old African American female with metastatic mucinous
ovarian carcinoma presented with a pelvic mass discovered during
her annual gynecological examination. An ultrasound showed adstein),
erson.org (N. Fleming),
rson.org (S. Piha-Paul).
. This is an open access article under7.7 × 8.7 cm left ovarian mass with complex appearance. The right
ovary appeared normal. Laparoscopic left salpingo-oophorectomy
showed a moderately differentiated mucinous ovarian carcinoma,
stage IC1, due to intraoperative rupture of the ovarian mass. Tumor
cells were diffusely positive for keratin 7 and very focally positive for
keratin 20. There was patchy expression of PAX-8 and DPC4 expression
was preserved. The patient was taken for diagnostic laparoscopy with
appendectomy, omentectomy, andmultiple peritoneal biopsies by a gy-
necologic oncologist; all of which were negative for malignancy.
Eight weeks later the patient started adjuvant chemotherapy with
one cycle of capecitabine and oxaliplatin (XELOX), transitioned to four
months of ﬂuorouracil and oxaliplatin (FOLFOX) due to insurance is-
sues. The CT abdomen and pelvis post FOLFOX chemotherapy showed
an enhancing 2.6 cm nodule in rectus abdominis muscle. The patient
underwent an exploratory laparotomy with excision of a 5 × 6 cm ab-
dominal mass involving fascia and muscle, consistent with metastatic
adenocarcinoma. The surgical resection margins were negative for ma-
lignancy. After recovery, the patient received chemotherapy with
carboplatin and paclitaxel for 6 months. The CT abdomen and pelvis
performed following 6 months of carboplatin and paclitaxel showed
progression of disease with new nodal and perihepatic implants.
The patient subsequently consulted with the MD Anderson Cancer
Center Department of Investigational Cancer Therapeutics for phase I
clinical trial options. The patient was treated with a phos-
phatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor plus a
Mitogen/Extracellular signal-regulated Kinase (MEK) inhibitor withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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phase I trial with a polymeric micellar nanoparticle of the substance
DACH-Pt (1,2-diaminocyclohexane platinum), an in vivo metabolite of
oxaliplatin, with progression following 1 cycle of therapy. The patient
was then enrolled in a trial with paclitaxel, bevacizumab and
temsirolimus (PAT). On the day of clearance to start treatment, she
was found to have a positive urine and serum pregnancy test. Her β-
hCG was 103. The patient was having regular menstrual cycles and
using two forms of birth control. Her husband previously had a
vasectomy.
The initial pelvic ultrasound showed no sonographic evidence of in-
trauterine or tubal gestation. The left ovary was surgically absent how-
ever the right ovary was enlarged with complex cystic mass with solid
components measuring 9.5 × 6.6 cm. The work-up for false positive el-
evation of β-hCG including serial dilutions, incorporation of animal
serumand outside institutional validation testing for β-hCG heterophile
antibody,was negative. Therefore, the β-hCG elevationwas not thought
to be related to a phantom hCG.
Dilation and curettage to rule out trophoblastic diseasewas planned,
but not completed due to discovery of a deep vein thrombosis and initi-
ation of therapeutic anticoagulation. As no intrauterine or extrauterine
pregnancy could be identiﬁed, after several weeks, the patient returned
to clinic andwas cleared to start treatment. At that time, her β-hCGwas
210.3. Three weeks post treatment with PAT, the β-hCG decreased to
27.5 and CT scans showed partial response (Fig. 1A,B). Shortly thereaf-
ter, the patient was admitted to the intensive care unit for weakness
due to Guillain Barre syndrome. She eventually transitioned to hospice
care.3. Discussion
Nearly all female patients undergoing enrollment on clinical trial are
evaluated for pregnancy as part of standard exclusion criteria. An ele-
vated β-hCG in the absence of viable pregnancy can occur for multiple
reasons and has a broad differential diagnosis includingmiscarriage, ec-
topic pregnancy, pituitary hCG production, trophoblastic disease and
phantom hCG. Ectopic pregnancy is frequently suspected when β-hCG
levels plateau or fail to double within 48 h without evidence of intra-
uterinepregnancywith ultrasound.When intrauterine and extrauterine
pregnancy are ruled out, other causes should be investigated.
Pituitary hCG may be produced in perimenopausal or postmeno-
pausal women. As estrogen and progesterone production decreases, re-
leasing gonadotropin releasing hormone (GnRH) from negative
feedback, luteinizing hormone (LH) and follicular stimulating hormone
(FSH) rise. The β subunit gene of LH is found in a sequence of 7 hCG β
subunit genes and therefore uncontrolled GnRH stimulation may lead
to hCG production by pituitary gonadotrope cells (Cole, 2005). Using
an FSH level of 45.0 mIU/ml identiﬁed hCG of perimenopausal
women, ages 41–55 years, withmildly increased serumhCG concentra-
tions (5.0–14.0mIU/ml), an FSH cutoff of 45.0mIU/ml identiﬁed hCG of
placental origin with 100% sensitivity and 75% speciﬁcity. FSH levels
greater than 45 mIU/ml were never observed when hCG was of placen-
tal origin. When hCG is less than 5.0 mIU/ml, FSH testing is not per-
formed as pregnancy is unlikely. When hCG is greater than 14.0 mIU/
ml, FSH testing is not performed as this is consistent with pregnancy
(Gronowski et al., 2008). In one study, two weeks of estrogen-proges-
terone therapy suppressed pituitary hCG andmay help conﬁrm diagno-
sis (Cole et al., 2007).
Gestational trophoblastic disease is a group of conditions that may
be classiﬁed as either premalignant, in the case of a partial or complete
hydatidiform mole, or malignant, including invasive mole, choriocarci-
noma, placental-site trophoblastic tumor and epithelioid trophoblastic
tumor. Although not always the case, β-hCG is commonly found to be
elevated in these conditions and these diseases are considered high on
the differential diagnosis list when found.Phantom hCG is a phenomenon ﬁrst described in 1998 by Laurence
Cole, Ph.D., where patients have persistentmild elevations of β-hCG, oc-
casionally following miscarriage. The elevated β-hCG often falsely
interpreted and misleads physicians to evaluate or incorrectly treat pa-
tients with cytotoxic agents for trophoblast disease (Cole, 1998).
Heterophilic antibodies against mouse, goat, rabbit, cow, horse, or
sheep antigens can interfere with two-site immunoassays by creating
complexes between the two anti-β-hCG antibodies without β-hCG
being present. This leads to a false-positive result (Vladutiu et al.,
1982). People can develop heterophilic antibodies by exposure to the
serum, tissue, or other antigens of nonhuman species. The incidence of
these antibodies in the general population is uncertain. Heterophilic an-
tibodies do not appear to be excreted in the urine and therefore urine
assays can be used to identify false-positive serum results. Serial dilu-
tions may also be performed to assess for interference. To avoid false
positives, manufacturers have incorporated animal serum and nonspe-
ciﬁc animal antibodies into all their test ingredients. The excess of non-
speciﬁc antibodies saturates heterophilic antibodies in human serum
and usually eliminates their interference with the assay (Johnson et
al., 2000). Additionally, serum samples can be sent to outside labora-
tories with different assay systems to validate results. In our
patient's case, the patient continued to have normal menstrual cy-
cles and was using two forms of contraception with her husband
who had history of vasectomy. The work up, including pelvic ultra-
sound and CT scans, was negative for pregnancy and trophoblastic
disease. The testing for heterophilic hCG antibodies was also nega-
tive. The patient additionally had a positive urine pregnancy test
inconsistent with phantom hCG. It was therefore believed that the
patient's β-hCG production was due to the patient's tumor, consis-
tent with a paraneoplastic syndrome.
Paraneoplastic syndromes occur in about 8% of cancer patients and
frequently develop with advanced disease. They may appear earlier
than symptoms of the primary tumor itself, leading to new diagnosis
of cancer (Pelosof and Gerber, 2010). β-hCG is primarily produced by
placental syncytiotrophoblast cells during pregnancy. It can also be
found in the testis, liver, lung, colon, and stomach in small amounts.Ma-
lignancies in these organs may lead to an increased serum levels
(Demirtas et al., 2007). A gastric origin is the most frequent, ranging
from 11% to 17% of this rare subset (Germann et al., 2002). In our case,
the patient had a primary ovarian neoplasm with metastases within
the abdomen. β-hCG levels rose while the patient was on a treatment
break, nearly impeding her from further treatment. With re-initiation
of therapy, the β-hCG declined, corresponding to a partial response
per Response Evaluation Criteria in Solid Tumors (RECIST) on radio-
graphic imaging. Urine hCG remained positive despite decline in
serum hCG as the level was still over the detection threshold of 25 IU/
l. Interesting enough, other tumor markers (CA 125, CA 15-3, CA 19.9
and CEA) all increased. The decreased size of tumor within the pelvis
corresponded with decreasing β-hCG levels while increased hepatic
metastasis corresponded to increases in other markers. This lends
evidence to the idea that the patient had tumoral heterogeneity
with different markers produced by tumors in different areas of
the body. This is the ﬁrst case of paraneoplastic β-hCG production
from an ovarian adenocarcinoma reported in the literature. We pro-
vide a treatment algorithm to evaluate for paraneoplastic hCG pro-
duction when assessing for clinical trial eligibility (Fig. 2).
Paraneoplastic syndrome should remain in the differential diagnosis
in patients found to have elevated levels of β-hCG without evidence
of intra- or extra-uterine pregnancy.Consent
Informed consent to publish the information was granted from the
patient.
None of the authors have conﬂict of interest or competing interest.
Fig. 1.A. Corresponding serum(IU/l) and urine (positive or negative) hCG assayswith treatment response over time. B. Corresponding serum tumormarkerswith treatment response over
time. Tumor markers correspond with disease progression in some tissues while hCG corresponds with disease response in other tissues.
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